home / stock / nlbif / nlbif news

NLBIF News and Press, New Age Brands From 12/21/20

Stock Information
Company Name: New Age Brands
Stock Symbol: NLBIF
Market: OTC
Menu
NLBIF NLBIF Quote NLBIF Short NLBIF News NLBIF Articles NLBIF Message Board
Get NLBIF Alerts

News, Short Squeeze, Breakout and More Instantly...
NLBIF - Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials

DENVER, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medic...
NLBIF - Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

DENVER, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourc...

NLBIF - Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics

The first Mydecine Speaker Series event will feature Mydecine Scientific Advisory Board Members Dr. Robin Carhart -Harris and Dr. Ruth Lanius , Chief Medical Officer Rakesh Jetly and Chief Scientific Officer Robert Roscow Moderated by ...

NLBIF - Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms

Mydecine completes harvest and is preparing to export 20 kilograms of psilocybin mushrooms from Jamaica to Canada for increased global supply scale of cGMP nature-sourced psilocybin DENVER, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCO...
NLBIF - Mydecine Innovations Group to Restate Financial Statements

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (the “ Company ”) (CSE:MYCO | OTC:MYCOF) announces that its previously issued financial statements for the fiscal year ended December 31, 2019, and the three- and six-month perio...

NLBIF - Mydecine Innovations Group Offers Management and Clinical Trials Update

Dr. Rakesh Jetly Appointed Chief Medical Officer Company Announces International Expansion of Clinical Trial Sites for Phase 2A Study into Psychedelic Treatments for PTSD in Veterans VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Mydecine Innova...

NLBIF - Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

VANCOUVER, British Columbia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead&#...
NLBIF - Mydecine Innovations Group Subsidiary NeuroPharm Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities

VANCOUVER, British Columbia, Oct. 14, 2020 (GLOBE NEWSWIRE) — NeuroPharm, Inc. (“NeuroPharm”), a wholly-owned subsidiary of  Mydecine Innovations Group Inc. (CSE:MYCO)(OTC:NLBIF)(FSE:0NF) (“Mydecine” or the “Company”) annou...

NLBIF - Mydecine Innovations Group subsidiary NeuroPharm Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities

VANCOUVER, British Columbia, Oct. 14, 2020 (GLOBE NEWSWIRE) -- NeuroPharm, Inc. (“NeuroPharm”), a wholly-owned subsidiary of Mydecine Innovations Group, Inc., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) announced today it has engaged FreeMind Group LLC to assist NeuroPharm in securin...

NLBIF - Mydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with Psilocybin

VANCOUVER, British Columbia, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce its wholly-owned subsidiary, NeuroPharm Inc. ("NeuroPharm”), has filed a provisional patent applicat...
Previous 10 Next 10